Table 4. RRs of second primary cancers after seminoma and non-seminoma.

Second cancer site	Seminoma			Non-seminoma
	Cases	RR1	95%CI2	Cases	RR	95%CI
All (excluding testis)	445	1.28	1.16–1.40	183	1.43	1.24–1.66
Upper aerodigestive tract	8	0.75	0.37–1.50	4	0.89	0.34–2.38
Esophagus	9	2.17	1.13–4.18	0	--	--
Stomach	14	1.67	0.99–2.82	2	0.72	0.18–2.88
Colorectum	46	1.26	0.94–1.68	21	1.64	1.07–2.51
Liver	9	1.30	0.67–2.49	3	1.22	0.39–3.78
Pancreas	12	1.64	0.93–2.89	2	0.79	0.20–3.16
Lung	21	0.79	0.51–1.21	15	1.62	0.98–2.69
Prostate	115	1.11	0.92–1.33	38	1.22	0.88–1.67
Testis	123	23.30	19.49–27.86	66	11.61	9.11–14.80
Kidney	23	2.22	1.48–3.34	9	2.20	1.15–4.23
Urinary bladder	34	1.57	1.12–2.19	19	2.57	1.64–4.03
Melanoma	22	1.15	0.76–1.74	9	1.10	0.61–1.98
Skin, squamous cell	21	1.35	0.88–2.08	11	1.87	0.97–3.59
Eye	3	2.87	0.92–8.90	0	--	--
Nervous system	17	1.53	0.95–2.46	7	1.12	0.53–2.34
Thyroid gland	6	3.19	1.43–7.10	2	1.75	0.44–7.01
Endocrine glands	7	1.48	0.70–3.10	0	--	--
Connective tissue	6	2.39	1.07–5.32	4	3.08	1.16–8.23
Non-Hodgkin lymphoma	26	1.96	1.33–2.88	10	1.73	0.93–3.21
Myeloma	5	1.05	0.44–2.51	4	2.36	0.89–6.29
Leukemia	21	1.96	1.28–3.00	10	2.16	1.16–4.02
Acute myeloid leukemia	8	4.27	2.13–8.55	2	2.42	0.60–9.68
Chronic myeloid leukemia	2	2.01	0.50–8.06	3	5.01	1.61–15.56
Acute lymphoid leukemia	2	4.42	1.10–17.71	1	2.73	0.38–19.38
Chronic lymphoid leukemia	6	1.55	0.69–3.45	1	0.75	0.10–5.29
Others	3	1.14	0.37–3.53	3	2.62	0.84–8.12
CUP3	12	1.44	0.82–2.53	6	1.99	0.89–4.43

RR¹ = relative risk, 95%CI² = 95% confidence interval, bold font indicates that the lower limit of 95%CI does not include 1.00. CUP³ = cancer of unknown primary.